Alvotech (ALVO)

Name: Alvotech (ALVO) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Alvotech (ALVO)

Stock Card

$5.20

$0.25 (5.05%)

As on 31-Aug-2026 10:33EDT

Market cap

$1,766 Mln

Revenue (TTM)

$492 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Alvotech (ALVO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.98 High: 5.22

52 Week Range

Low: 2.94 High: 9.25

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

20.1
Debt to Equity

0
Book Value

$--
EPS

$-0.6
Face value

--
Shares outstanding

356,817,038

5 Years Aggregate

CFO

$-1,015.59 Mln

EBITDA

$-1,002.60 Mln

Net Profit

$-1,546.74 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Alvotech (ALVO)	1.4	45.7	54.8	-35.6	-18.8	-11.9	--
BSE Sensex	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5

As on 31-Aug-2026

Company	2025	2023
Alvotech (ALVO)	-61.2	14.8
BSE Sensex	9.1	18.7
BSE Sensex	9.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Alvotech (ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a... high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. Read more